
Verve Therapeutics, Inc. (NASDAQ: VERV) related to its sale to Eli Lilly. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones.